Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

被引:27
|
作者
Kuwata, Hitoshi [1 ,2 ]
Yabe, Daisuke [1 ,3 ,4 ]
Murotani, Kenta [5 ]
Fujiwara, Yuuka [1 ]
Haraguchi, Takuya [1 ,2 ,3 ]
Kubota, Sodai [1 ,3 ]
Kubota-Okamoto, Saki [1 ,3 ]
Usui, Ryota [1 ,2 ]
Ishitobi, Minori [2 ]
Yamazaki, Yuji [1 ,2 ]
Hamamoto, Yoshiyuki [1 ,2 ]
Kurose, Takeshi [1 ,6 ]
Seino, Yusuke [7 ]
Yamada, Yuichiro [1 ,2 ]
Seino, Yutaka [1 ,2 ]
机构
[1] Kansai Elect Power Med Res Inst, Yutaka Seino Distinguished Ctr Diabet Res, Kobe, Hyogo, Japan
[2] Kansai Elect Power Hosp, Ctr Diabet Endocrinol & Metab, Osaka, Japan
[3] Gifu Univ, Grad Sch Med, Dept Diabet Endocrinol & Metab, Gifu, Japan
[4] Kobe Univ, Grad Sch Med, Div Mol & Metab Med, Kobe, Hyogo, Japan
[5] Kurume Univ, Grad Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan
[6] Nakanoshima Clin, Osaka, Japan
[7] Fujita Hlth Univ, Dept Endocrinol & Metab, Toyoake, Aichi, Japan
关键词
Gastric emptying; GLP-1 receptor agonist; islet hormones; OPEN-LABEL; INCRETIN SECRETION; LIRAGLUTIDE; LIXISENATIDE; GLP-1; STIMULATION; GLUCOSE; SAFETY; GIP;
D O I
10.1111/jdi.13598
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. Materials and Methods A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. Results Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs. Conclusions All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.
引用
收藏
页码:2162 / 2171
页数:10
相关论文
共 50 条
  • [41] Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabet Reply
    Foer, Dinah
    Beeler, Patrick E.
    Cui, Jing
    Karlson, Elizabeth W.
    Bates, David W.
    Cahill, Katherine N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (07) : 924 - 925
  • [42] PRESENT AND FUTURE OF THE RELATIONSHIP BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES
    Pozzilli, Paolo
    Napoli, Nicola
    Naciu, Anda Mihaela
    Soare, Andreea
    INTERDIAB 2017: DIABETES MELLITUS IN INTERNAL MEDICINE, 2017, : 78 - 85
  • [43] Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
    Resnick, Ortal
    Bril, Fernando
    Beauchamp, Giovanna
    FRONTIERS IN ENDOCRINOLOGY, 2025, 15
  • [44] Comparison of short-and long-acting glucagon-like peptide 1 receptor agonists on postprandial glucose excursion, insulin and glucagon secretions and gastric emptying
    Kuwata, Hitoshi
    Yabe, Daisuke
    Nagata, Takeru
    Kubota, Sodai
    Okamoto, Saki
    Ueno, Shinji
    Sakuramachi, Yui
    Watanabe, Koin
    Hyo, Takanori
    Tanaka, Nagaaki
    Hamamoto, Yoshiyuki
    Kurose, Takeshi
    Seino, Yutaka
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S124 - S125
  • [45] Effects of glucagon-like peptide-1 receptor agonists on renal function
    Filippatos, Theodosios D.
    Elisaf, Moses S.
    WORLD JOURNAL OF DIABETES, 2013, 4 (05) : 190 - 201
  • [46] Glucagon-like peptide-1 receptor agonists and their effects on weight reduction
    Shin, Shyi-Jang
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (06) : 490 - 491
  • [47] Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
    Chilton, Robert J.
    JOURNAL OF DIABETES & METABOLISM, 2015, 6 (01)
  • [48] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Ashish Sarraju
    Sun H. Kim
    Joshua W. Knowles
    Current Atherosclerosis Reports, 2016, 18
  • [49] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Sarraju, Ashish
    Kim, Sun H.
    Knowles, Joshua W.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (02) : 1 - 8
  • [50] Gastric ultrasound and mitigating risk of glucagon-like peptide-1 receptor agonists
    Hurley, Cian
    Kearsley, Rosemarie
    ANAESTHESIA, 2024, 79 (10) : 1131 - 1132